UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000051654
Receipt number R000058875
Scientific Title Estimation of Socioeconomic Burden of Adult Attention-Deficit/Hyperactivity Disorder (ADHD) in Japan
Date of disclosure of the study information 2023/07/20
Last modified on 2023/07/13 11:03:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Estimation of Socioeconomic Burden of Adult Attention-Deficit/Hyperactivity Disorder (ADHD) in Japan

Acronym

Socioeconomic costs of adult ADHD in Japan.

Scientific Title

Estimation of Socioeconomic Burden of Adult Attention-Deficit/Hyperactivity Disorder (ADHD) in Japan

Scientific Title:Acronym

Socioeconomic costs of adult ADHD in Japan.

Region

Japan


Condition

Condition

Attention-Deficit/Hyperactivity Disorder (ADHD)

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The objective is to estimate the socioeconomic burden of adult ADHD in Japan per year.

Basic objectives2

Others

Basic objectives -Others

The purpose of this study is to estimate the socioeconomic burden of adult ADHD in Japan per year. The socioeconomic burden includes the costs of healthcare resources and social security services utilized by adult ADHD patients, productivity loss in adult ADHD patients, and productivity loss in adult family members of adult ADHD patients.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Socioeconomic Burden of Adult ADHD
The costs of medical care, social security services, and productivity loss (the cost of lost employment, reduced salary and reduced work productivity defined by absenteeism and presenteeism) in adult ADHD patients and productivity loss in adult families of adult ADHD patients and their aggregate values are estimated.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

web-based questionnaire Survey
-Those who were willing to participate in the survey, understood the contents of the informed consent form for the survey, and gave consent to participation in the survey
-Male or female patients >= 18 to < 65 years of age at the time of informed consent.
-The subject are living in Japan at the time of the questionnaire.

Inclusion criteria for each study population are as follows:
-Adult ADHD patients: individuals who have diagnosis of ADHD
-Adult families of adult ADHD patients: individuals who do not have diagnosis of ADHD, family members living together are diagnosed with ADHD and aged 18 years or older.
-ASRS-positive non-ADHD adults: individuals who do not have diagnosis of ADHD, family members living together have not been diagnosed with ADHD, and ASRS*-positive(>= 4)**
-ASRS-negative non-ADHD adults: individuals who do not have diagnosis of ADHD, family members living together have not been diagnosed with ADHD, and ASRS negative(< 4)
**At least 4 out of 6 questions about symptom frequency in Part A of the Japanese version of the Adult ADHD Self-Report Scale (ASRS, v1.1) are above the prespecifi edcriteria.

Database analysis
-Patients diagnosed with 'other mental and behavioral disorders' (including ADHD), and having a health insurance claim in the JMDC database
-Patients registered in the JMDC database for the year to be analysed
-For ADHD, the patients aged >= 18 and < 65 years in the year to be analysed

Key exclusion criteria

A web-based questionnaire Survey
-Not applicable

Database analysis
-Not applicable

Target sample size

1800


Research contact person

Name of lead principal investigator

1st name Nobuhiro
Middle name
Last name Nishigaki

Organization

Takeda Pharmaceutical Company Limited.

Division name

Japan Medical Offi ce

Zip code

103 - 8668

Address

2-1-1 Nihonbashi Honcho, Chuo-ku, Tokyo

TEL

03-3278-2111

Email

nobuhiro.nishigaki@takeda.com


Public contact

Name of contact person

1st name Nobuhiro
Middle name
Last name Nishigaki

Organization

Takeda Pharmaceutical Company Limited.

Division name

Japan Medical Offi ce

Zip code

103 - 8668

Address

2-1-1 Nihonbashi Honcho, Chuo-ku, Tokyo

TEL

03-3278-2111

Homepage URL


Email

nobuhiro.nishigaki@takeda.com


Sponsor or person

Institute

Takeda Pharmaceutical Company Limited.

Institute

Department

Personal name



Funding Source

Organization

Takeda Pharmaceutical Company Limited.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

NPO MINS Institutional Review Board

Address

ST Shibuya Building 2F, 1-15-14 Dogenzaka, Shibuya-ku, Tokyo

Tel

03-6416-1868

Email

npo-mins@j-irb.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 07 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 07 Month 05 Day

Date of IRB

2023 Year 07 Month 20 Day

Anticipated trial start date

2023 Year 07 Month 24 Day

Last follow-up date

2023 Year 07 Month 28 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

N/A


Management information

Registered date

2023 Year 07 Month 20 Day

Last modified on

2023 Year 07 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000058875


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name